Shin Nippon Biomedical LaboratoriesSBLOF -2.13%74 ROC (Joel Greenblatt) % is 34.18% as of Mar. 2026, which is 64% above its 10-year median of 20.90. GuruFocus rates SBLOF with a GF Score™ of 74/100 and a GF Value™ of $14.04. The stock has 5 warning signs investors should review. Among 211 Medical Diagnostics & Research companies, Shin Nippon Biomedical Laboratories ranks better than 68.25% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Shin Nippon Biomedical Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 34.18%.
The historical rank and industry rank for Shin Nippon Biomedical Laboratories's ROC (Joel Greenblatt) % or its related term are showing as below:
SBLOF'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -6.35 Med: 20.9 Max: 63.79
Current: 16.22
During the past 13 years, Shin Nippon Biomedical Laboratories's highest ROC (Joel Greenblatt) % was 63.79%. The lowest was -6.35%. And the median was 20.90%.
SBLOF's ROC (Joel Greenblatt) % is ranked better than 68.25% of 211
companies
in the Medical Diagnostics & Research industry
Industry Median: -3.02
vs SBLOF: 16.22
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SBLOF vs TMO, DHR, IDXX: ROC (Joel Greenblatt) % Comparison
For the Diagnostics & Research subindustry, Shin Nippon Biomedical Laboratories's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shin Nippon Biomedical Laboratories ROC (Joel Greenblatt) % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Shin Nippon Biomedical Laboratories's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Shin Nippon Biomedical Laboratories's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 34.18% mean?
Shin Nippon Biomedical Laboratories (SBLOF) has a ROC (Joel Greenblatt) % of 34.18% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Shin Nippon Biomedical Laboratories and its competitors. This is 64% above median its historical median of 20.90. According to the industry distribution chart, Shin Nippon Biomedical Laboratories ranks #67 out of 211 companies in the Medical Diagnostics & Research industry, placing it in the top 31.8%.
Is Shin Nippon Biomedical Laboratories' ROC (Joel Greenblatt) % too high?
Shin Nippon Biomedical Laboratories' current ROC (Joel Greenblatt) % of 34.18% is 64% above median its 10-year median of 20.90. Based on the distribution chart, Shin Nippon Biomedical Laboratories ranks #67 out of 211 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Shin Nippon Biomedical Laboratories has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does Shin Nippon Biomedical Laboratories' ROC (Joel Greenblatt) % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Shin Nippon Biomedical Laboratories ranks #67 out of 211 companies for ROC (Joel Greenblatt) %. This puts Shin Nippon Biomedical Laboratories in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Diagnostics & Research company?
A good ROC (Joel Greenblatt) % depends on the Medical Diagnostics & Research industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Shin Nippon Biomedical Laboratories and its competitors. Shin Nippon Biomedical Laboratories's current ROC (Joel Greenblatt) % is 34.18%, which is 64% above median its own 10-year median of 20.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shin Nippon Biomedical Laboratories stock overvalued right now?
Shin Nippon Biomedical Laboratories (SBLOF) has a current ROC (Joel Greenblatt) % of 34.18%. The stock's GF Value™ is $14.04, compared to a current price of $9.16 — trading 34.8% below its estimated fair value. The current ROC (Joel Greenblatt) % is 34.18%, which is 64% above median its 10-year median of 20.90. Shin Nippon Biomedical Laboratories' overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Shin Nippon Biomedical Laboratories (SBLOF), the current ROC (Joel Greenblatt) % is 34.18% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shin Nippon Biomedical Laboratories (SBLOF) Overvalued in 2026?
Based on GuruFocus' analysis, Shin Nippon Biomedical Laboratories stock appears to be undervalued.
The current stock price of $9.16 is trading 34.8% below its estimated GF Value™ of $14.04.
Key valuation signals for SBLOF:
ROC (Joel Greenblatt) %: 34.18% (64% above median its 10-year median of 20.90)
GF Value™: $14.04 vs. price of $9.16 (34.8% below fair value)
No single metric tells the full story. See the SBLOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shin Nippon Biomedical Laboratories Business Description
Shin Nippon Biomedical Laboratories Ltd provides pre-clinical testing services in the pharmaceutical industry in Japan. The company provides a range of services such as pre-clinical and analysis studies, contracted clinical trials, SMO, CRO, translational research and cancer treatment.
74GF Score
Get the complete analysis for SBLOF
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SBLOF has been successfully added to your 
